Engler and Prantl system of classification in plant taxonomy
Candidate 113701 (srg) senior biologist
1. Submitted by: Jonathan Duckworth Contact Number: 01223 394235
Candidate Name: Candidate 113701
Location: West Sussex, but looking to relocate to Cambridge
Salary Expectations: £35,000+
Current Role:
Lead Scientist
Desired Role:
Senior Scientist
Notice Period:
Available from late June 2014
Relevant Experience/Skills
For Role:
A Senior Cell Biologist with 12 yrs experience in the drug
discovery industry, the majority of which have been working on
projects for oncology therapeutic targets (PI3K and Protein
homeostasis.
Very competent in a range of cell biology assays (2D/3D
proliferation, migration/invasion) as well as having a strong
repertoire of general laboratory skills.
In his current role as a lab group head, he is engaged with a
number of different discovery project teams where he presents and
interprets the data generated by the group to influence project
decision making.
Actively looking to move to the Cambridge area.
2. C A N D I D A T E 1 1 3 7 0 1
Profile
A successful drug discovery scientist with 12 years experience in both small biotech and large
pharma setting, working on projects delivering a candidate drugs from the bench to the clinic.
Practical cell biology experience investigating small molecule pharmacology in both respiratory
disease and oncology research fields. An accomplished communicator with strong analytical
skills and a positive approach to team work.
Key Skills
Cell Biology
Culture of differentiated near primary bronchial epithelial cells (BECs) in 2D and 3D
(bronchosphere) formats
Proliferation, migration and 3D growth assay with oncology cell lines
General Biology
ELISA, Western blotting, Immunofluorescence, confocal microscopy, nucleic acid
extraction and gene expression profiling
Software
Spotfire, Graphpad prism, XLfit
Employment History
Novartis Institute for Biomedical Research (NIBR), Horsham UK
2011 – Present Scientist II
Leading a small group specialising in respiratory epithelial ion transport – working with
differentiated cultures of near primary bronchial epithelial cells to provide high quality
screening data for several respiratory disease project teams as well as more bespoke studies
for target validation and compound mode of action.
Design and execution of experiments for ion transport drug combinations and validation
of literature targets for CFTR modulation
Assessment of a 3D organoid (bronchosphere) culture as a phenotypic screening tool
Investigation of the impact of cell culture medium on the differentiation of BECs in air
liquid interface cultures using IF and RNA expression data
Exploratory work on models of live respiratory viral infection of BEC cultures including
virus culture (RSV, hRV16, Influenza) and design of a low density Taqman array to
probe epithelial host defence response to viral challenge
Working with an academic collaborator to transfer a new technology for increased
assay throughput
Active participation in project teams including interpretation of data to facilitate decision
making with a 3rd
party collaborator
Report writing to support regulatory submissions
2010 – 2011 Scientist I
Lab scientist with supervisory responsibility, coordinating the delivery of ion transport data to
project teams in the respiratory disease department
Ussing chamber studies with diseased/non-diseased bronchial epithelial cells
Generation and presentation of decision making data to support clinical candidate
selection for a respiratory disease project
2009 – 2010 Contract scientist (SRG)
Lab scientist working on an ion transport project with a focus on infectious secretory diarrhea
Ussing chamber studies with both engineered and physiologically relevant cell lines
Data analysis and reporting to the project team
3. Piramed Pharma, Slough UK
2007 – 2008 Senior Research Associate
Key member of a research team identifying mutation hotspots that could cause resistance to a
clinical candidate drug.
Design of resistance selection strategy
Optimisation of transfection conditions for retroviral library generation
Infection of target cell line and colony selection/expansion for gene sequencing.
2003 – 2007 Research Associate
Member of the cell biology group running a range of in vitro assays supporting compound
selection and target validation
In house set-up of cell line based in vitro assays to increase target validation
o Migration or invasion through matrigel layer in transwell inserts
o Growth of spheroids in semisolid methylcellulose
Sourced and implemented an automated microscopy system to enable quantification of
stained tumour sections
Established qRT-PCR capability in house; purchased equipment and developed software
skills in micro-array data analysis
Performing proliferation assays (Alamar Blue) in a range of cancer cell lines to support
compound progression
Millennium Pharmaceuticals R&D Ltd , Cambridge UK
2001 – 2003 Research Associate
Responsibility for running all in vitro enzyme assays for a high priority oncology project. Carried
out optimisation and troubleshooting of assays to ensure timely delivery of data for
presentation at project team meetings in both UK & US.
Primary target and follow-up selectivity screening in an isolated enzyme HTRF assay
Competency in use of lab automation equipment including Multiprobe, Platemate Plus
and Serialmate liquid handling systems
Education
2000 – 2001 University of Nottingham UK
MSc with Distinction: Applied Biomolecular Technology
3 month research placement: Y Chromosome Analysis of the Wirral Population
1996 – 1999 University of Leeds UK
BSc (Hons) 2ii: Biochemistry and Molecular Biology
Publications
Raynaud FI, et al Biological properties of potent inhibitors of class I
phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-
620 to the oral agent GDC-0941. Mol Cancer Ther 2009; 8:1725–38.
Folkes AJ, et al The Identification of 2-(1H-Indazol-4-yl)-6-(4-
methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-
thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally
Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of
Cancer. J Med Chem 2008; 51 (18): 5522-5532
INTERESTS
Skiing/snowboarding
Woodwork/Furniture making and upholstery